Caroline M Tanner, MD
Neurology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
Offices
1 location · University of California San Francisco · 1,780 clinicians in this group
Looking this up.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tanner’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G68771 · Current
Licensed to practise in California · since 1990 · expires 2027-11-30 · Loyola University of Chicago Stritch School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$3,316
Pharmacies billed $3,316 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 43) in 2024. Too few prescriptions to compare fairly with other clinicians.
43 generic and 0 brand-name prescriptions · $3,316 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Carbidopa-Levodopa | 16 | $1,234 | $77 |
| Carbidopa-Levodopa Er | 11 | $326 | $30 |
Year by year
| 2024 | 43 | None | 0% (0) | 0% | $3,316 |
| 2023 | 54 | None | None | None | $16,018 |
| 2022 | 34 | None | None | None | $7,784 |
| 2021 | 37 | None | None | None | $7,790 |
| 2020 | 50 | None | None | None | $8,884 |
| 2019 | 49 | None | None | None | $10,236 |
| 2018 | 35 | None | None | 51% | $37,962 |
| 2017 | 31 | None | None | 58% | $29,261 |
| 2016 | 58 | None | None | 69% | $34,062 |
| 2015 | 66 | None | 0% (0) | 50% | $19,926 |
| 2014 | 84 | None | 0% (0) | 56% | $33,100 |
| 2013 | 154 | 11 | 0% (0) | 29% | $36,426 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Carbidopa-Levodopa | 14 | $1,278 | $91 |
| Carbidopa-Levodopa Er | 14 | $853 | $61 |
2022: 1 drug
| Carbidopa-Levodopa | 12 | $1,168 | $97 |
2020: 1 drug
| Carbidopa-Levodopa | 13 | $762 | $59 |
2019: 1 drug
| Carbidopa-Levodopa | 15 | $1,260 | $84 |
2018: 1 drug
| Nuplazid | Parkinson's psychosis | 11 | $30,991 | $2,817 |
2017: 1 drug
| Nuplazid | Parkinson's psychosis | 12 | $26,354 | $2,196 |
2016: 2 drugs
| Azilect | 24 | $14,832 | $618 |
| Carbidopa-Levodopa | 12 | $1,224 | $102 |
2015: 2 drugs
| Azilect | 18 | $10,658 | $592 |
| Carbidopa-Levodopa | 19 | $1,666 | $88 |
2014: 3 drugs
| Azilect | 23 | $13,236 | $575 |
| Silenor | 13 | $4,035 | $310 |
| Carbidopa-Levodopa | 15 | $2,210 | $147 |
2013: 5 drugs
| Azilect | 28 | $14,124 | $504 |
| Carbidopa-Levodopa | 35 | $5,672 | $162 |
| Ropinirole | 20 | $4,272 | $214 |
| Amantadine | 18 | $1,866 | $104 |
| Pramipexole Dihydrochloride | 18 | $995 | $55 |
Money from drug and device companies
$7,532 in 2025
| 2025 | 1 | 8 | $6,220 | $7,532 |
| 2024 | 3 | 12 | $21,870 | $25,005 |
| 2023 | 8 | 13 | $6,450 | $7,069 |
| 2022 | 3 | 5 | $7,380 | $7,401 |
| 2021 | 2 | 4 | $10,000 | $10,000 |
| 2020 | 1 | 1 | $2,000 | $2,000 |
| 2019 | 6 | 22 | $15,421 | $17,505 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | None | $7,532 | 8 payments
|
See all 8 published payments
| Genentech USA | Travel · 2025-03-15 | None | $146 |
| Genentech USA | Meals · 2025-03-15 | None | $57 |
| Genentech USA | Meals · 2025-03-15 | None | $73 |
| Genentech USA | Meals · 2025-03-15 | None | $65 |
| Genentech USA | Travel · 2025-03-15 | None | $232 |
| Genentech USA | Consulting · 2025-03-15 | None | $6,220 |
| Genentech USA | Travel · 2025-03-15 | None | $595 |
| Genentech USA | Meals · 2025-03-14 | None | $145 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $25,005
| Neurocrine Biosciences | Ingrezza | $23,650 | 8 payments
|
| Genentech | None | $1,200 | 1 payment
|
| Boston Scientific | None | $155 | 3 payments
|
2023: $7,069
| MDD US Operations | Gocovri | $3,622 | 4 payments
|
| Genentech | None | $3,000 | 2 payments
|
| Medtronic | Percept PC Brainsense | $139 | 1 payment
|
| Supernus Pharmaceuticals | None | $112 | 2 payments
|
| Eisai | None | $90 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $64 | 1 payment
|
| Boston Scientific | None | $25 | 1 payment
|
| AbbVie | Duopa | $18 | 1 payment
|
2022: $7,401
| Jazz Pharmaceuticals | None | $3,990 | 2 payments
|
| Genentech | None | $3,390 | 2 payments
|
| Abbvie | Botox | $21 | 1 payment
|
2021: $10,000
| Jazz Pharmaceuticals | Sunosi | $6,000 | 2 payments
|
| Kyowa Kirin Pharmaceutical Development | None | $4,000 | 2 payments
|
2020: $2,000
| H. Lundbeck A S | None | $2,000 | 1 payment
|
2019: $17,505
| Acorda Therapeutics | None | $10,838 | 7 payments
|
| Amneal Pharmaceuticals | Rytary | $4,459 | 5 payments
|
| Biogen | None | $1,561 | 3 payments
|
| Medtronic USA | Activa | $359 | 4 payments
|
| Neurocrine Biosciences | Ingrezza | $175 | 2 payments
|
| Adamas Pharmaceuticals | Gocovri | $113 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · A Phase 2b Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease · 2025 | Their institution | $615,027 |
| Genentech, Inc. · A Phase 2b Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease · 2023 | Their institution | $474,481 |
| Genentech, Inc. · A Phase 2b Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease · 2024 | Their institution | $365,180 |
| Roche TCRC, Inc. · Phase II Study in Early Stage Parkinson S Disease Patients · 2019 | Their institution | $272,407 |
| Roche TCRC, Inc. · Phase II Study in Early Stage Parkinson S Disease Patients · 2024 | Their institution | $247,912 |
| Roche TCRC, Inc. · Phase II Study in Early Stage Parkinson S Disease Patients · 2025 | Their institution | $232,876 |
| Biogen, Inc. · Research Agreement, Tracking Id# 169520, NPI; Yes, UCSF (Tanner, Caroline MD), Study for Early Identification & Prognosis Neurodegenerative Parkinsonism · 2019 | Their institution | $231,353 |
| Roche TCRC, Inc. · Phase II Study in Early Stage Parkinson S Disease Patients · 2022 | Their institution | $163,153 |
| Roche TCRC, Inc. · Phase II Study in Early Stage Parkinson S Disease Patients · 2020 | Their institution | $150,445 |
| Genentech, Inc. · A Phase 2b Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease · 2022 | Their institution | $145,640 |
| Roche TCRC, Inc. · Phase II Study in Early Stage Parkinson S Disease Patients · 2021 | Their institution | $101,330 |
| Biogen, Inc. · Research Agreement, Tracking Id# 169520, NPI; Yes, UCSF (Tanner, Caroline MD), Study for Early Identification & Prognosis Neurodegenerative Parkinsonism · 2021 | Their institution | $77,118 |
| Biogen, Inc. · Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Participants With Parkinson'S Disease · 2019 | This clinician | $11,875 |
| Biogen, Inc. · Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Biib054 in Participants With Parkinson'S Disease · 2020 | This clinician | $7,125 |
| Neurocrine Biosciences, Inc. · A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia · 2020 | This clinician | $3,296 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1043256035
- Licence
- CA G68771California G68771: Current · expires 2027-11-30
- Trained
- Loyola University of Chicago, Stritch School of Medicine, 1976
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 173000000X (173000000X)
- Mailing address
- 675 Almanor Ave, Sunnyvale, CA, 94085
- NPI first listed
- 2006-06-20
- NPI last updated
- 2013-01-29
This is when the NPI record was last certified, not a medical board exam.